Sugi Predict

Sugi Predict / Compounds / SCHEMBL2709514

SCHEMBL2709514

SCHEMBL2709514

CC1(C)OB(c2ccc3c(C(=O)O)cccc3c2)OC1(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 1/20 0.51
▸ NR4A1 P22736 1/20 0.46
▸ NR4A2 P43354 1/20 0.46
▸ NR4A3 Q92570 1/20 0.46
▸ LIPG Q9Y5X9 5/20 0.43
▸ LPL P06858 4/20 0.43
▸ P4HB P07237 1/20 0.41
▸ CDC25B P30305 3/20 0.39
▸ TBXAS1 P24557 1/20 0.38
▸ GRIN2D O15399 1/20 0.38
▸ GRIN2A Q12879 1/20 0.38
▸ GRIN2B Q13224 1/20 0.38
▸ GRIN2C Q14957 1/20 0.38
▸ F2 P00734 2/20 0.38
▸ F11 P03951 2/20 0.38
▸ PRSS1 P07477 2/20 0.38
▸ PRSS2 P07478 2/20 0.38
▸ PRSS3 P35030 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1669436 0.89 LIPG (0.47) PTPN1NR4A1NR4A2NR4A3LIPG
SCHEMBL2382334 0.85 PDE4B (0.48) LIPGLPLP4HBKDM4EALDH1A1
SCHEMBL29549737 0.84 NPC1 (0.48) HPGD
SCHEMBL28980456 0.82 LIPG (0.40) LIPGLPLP4HBF2F11
SCHEMBL17749164 0.80 KMT2A (0.50) —
SCHEMBL29549742 0.80 NPC1 (0.58) HSD17B10
SCHEMBL29549610 0.79 AKR1C3 (0.44) ALDH1A1
SCHEMBL29550088 0.79 KDR (0.46) KDM4EALDH1A1HPGD
SCHEMBL18579778 0.79 AKR1C3 (0.44) ALDH1A1
SCHEMBL29549981 0.79 KDR (0.47) KDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107108631-B 6-amino-7-bicyclic-7-deaza-purine derivatives as protein kinase inhibitors 内尔维阿诺医学科学有限公司 2020-06-16 — — CN disclosed
US-10221181-B2 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2019-03-05 — — US disclosed
US-10221181-B2 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2019-03-05 — — US disclosed
US-20170327506-A1 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS NERVIANO MEICAL SCIENCES S.r.l. (IT) 2017-11-16 — — US disclosed
US-20170327506-A1 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS NERVIANO MEICAL SCIENCES S.r.l. (IT) 2017-11-16 — — US disclosed
US-20170327506-A1 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS NERVIANO MEICAL SCIENCES S.r.l. (IT) 2017-11-16 — — US disclosed
US-9771345-B2 Coferons and methods of making and using them CORNELL UNIVERSITY (US) 2017-09-26 — — US disclosed
US-9771345-B2 Coferons and methods of making and using them CORNELL UNIVERSITY (US) 2017-09-26 — — US disclosed
US-9771345-B2 Coferons and methods of making and using them CORNELL UNIVERSITY (US) 2017-09-26 — — US disclosed
EP-3218378-A1 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2017-09-20 — — EP disclosed
US-20120172386-A1 Combinations Comprising a VEGF Receptor Inhibitor NOVARTIS AG (CH) 2012-07-05 — — US disclosed
EP-1945217-B1 COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER NOVARTIS AG (CH) 2012-05-02 — — EP disclosed
US-20110301157-A1 BICYCLIC AMIDES AS KINASE INHIBITORS NOVARTIS AG 2011-12-08 — — US disclosed
WO-2011043817-A1 COFERONS AND METHODS OF MAKING AND USING THEM CORNELL UNIVERSITY (US) 2011-04-14 — — WO disclosed
US-20080306058-A1 Combinations Comprising a Vegf Receptor Inhibitor NOVARTIS AG 2008-12-11 — — US disclosed
US-20080287427-A1 Bicyclic Amides as Kinase Inhibitors NOVARTIS AG (CH) 2008-11-20 — — US disclosed
EP-1945217-A2 COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER Novartis AG (CH) 2008-07-23 — — EP disclosed
EP-1794149-A2 BICYCLIC AMIDES AS KINASE INHIBITORS Novartis AG (CH) 2007-06-13 — — EP disclosed
WO-2007031265-A2 COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER NOVARTIS AG (CH) 2007-03-22 — — WO disclosed
WO-2006059234-A2 BICYCLIC AMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2006-06-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306058-A1 Combinations Comprising a Vegf Receptor Inhibitor KDR, FLT4, FLT1 PTPN1 2181/4885NR4A1 273/4885NR4A2 227/4885
US-20110301157-A1 BICYCLIC AMIDES AS KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K19 PTPN1 1642/4885NR4A1 3730/4885NR4A2 3536/4885
US-20170327506-A1 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS DCK, RET, ADK PTPN1 1038/4885NR4A1 2692/4885NR4A2 2231/4885
US-20080287427-A1 Bicyclic Amides as Kinase Inhibitors MAP3K20, MAP3K1, MAP3K19 PTPN1 1745/4885NR4A1 3602/4885NR4A2 3380/4885
US-10221181-B2 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors DCK, RET, PRKCA PTPN1 1194/4885NR4A1 2646/4885NR4A2 2094/4885
US-20120172386-A1 Combinations Comprising a VEGF Receptor Inhibitor KDR, FLT4, FLT1 PTPN1 2181/4885NR4A1 273/4885NR4A2 227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.